, Volume 25, Issue 6, pp 2057-2058
Date: 26 Oct 2010

Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and impact of anti-tumor necrosis factor on postoperative outcomes

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The anti-tumor necrosis factor alpha (infliximab) has become an effective drug in the medical treatment of moderate or severe ulcerative colitis [1]. Infliximab can delay the incidence of complications and disease progression. However, the definitive treatment of ulcerative colitis is a surgical approach. Restorative proctocolectomy (RPC) with ileal pouch-anal anastomosis (IPAA) remains the standard of care for most patients with ulcerative colitis [2]. The short-term postoperative outcomes can substantially be improved by laparoscopic surgery for gastrointestinal diseases, including colorectal cancer and gastric cancer [39]. This advance in laparoscopic surgery has been translated into laparoscopic restorative proctocolectomy (LRPC) with IPAA for the treatment of ulcerative colitis [10]. However, the impact of medical treatment with infliximab on a subsequent surgical treatment is unclear and because the data are still scarce, there is debate whether infliximab increases postoperativ